For the roughly 40 million Americans who swallow a statin pill every morning, the routine is simple but relentless: miss enough days and LDL cholesterol creeps back up, dragging cardiovascular risk with it. A small clinical trial now suggests that a single intravenous infusion could do what those daily pills do, and keep doing it for at least a year without another dose. The therapy, called VERVE-102 and developed by Verve Therapeutics, uses a gene-editing technique to permanently disable the liver gene responsible for producing a protein called PCSK9. In results published in the New England Journal of Medicine and presented in 2025, the highest dose tested cut PCSK9 protein by roughly 55% and LDL cholesterol by up to 55% in a small Phase 1b cohort, with those reductions holding steady through 12 months of follow-up.
The findings arrive at a moment when the FDA has already approved a separate injectable cholesterol drug for the same high-risk patients, setting up a direct contest between two fundamentally different strategies for replacing the daily pill.
How VERVE-102 works and what the trial showed
VERVE-102 relies on a method called in vivo base editing. Delivered by lipid nanoparticle infusion, the therapy enters liver cells and changes a single DNA letter in the PCSK9 gene, effectively switching it off. PCSK9 normally breaks down the receptors on liver cells that pull LDL cholesterol out of the bloodstream. Silence the gene and those receptors stay active longer, clearing more of the artery-clogging particles that drive heart attacks and strokes.
The Phase 1b trial enrolled a small group of patients with heterozygous familial hypercholesterolemia, a genetic condition that keeps LDL dangerously elevated from birth. Participants received a single infusion at escalating doses. The peer-reviewed data showed dose-dependent drops in both PCSK9 and LDL, with the strongest responses at the highest dose level. Critically, the reductions did not fade over the 12-month observation window, consistent with the idea that a permanent DNA change produces a durable effect.
The trial was designed primarily to assess safety and tolerability, not to prove that the therapy prevents heart attacks. No serious safety signals were reported in the published data, though the small sample size limits what can be concluded about rare adverse events. Detailed off-target editing analyses have not yet been fully reported in the public literature.
The drug it will be measured against
The most direct comparison for VERVE-102 is inclisiran, marketed by Novartis under the brand name Leqvio. The FDA approved inclisiran for adults with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia whose LDL stays too high despite maximum statin therapy. Rather than editing DNA, inclisiran uses RNA interference to temporarily block the messenger RNA that tells liver cells to make PCSK9. The effect wears off, so patients need two injections a year after an initial loading dose.
Inclisiran’s clinical evidence is far more extensive. Two large Phase 3 trials, ORION-10 and ORION-11, enrolled more than 3,000 patients combined and showed that the drug reduced LDL cholesterol by approximately 50% at day 510 compared with placebo. Earlier Phase 2 data from the ORION-1 trial demonstrated meaningful LDL reductions lasting a full year after a single dose. Those results established that targeting PCSK9 with infrequent injections can match or exceed what daily statins achieve for many patients.
At a U.S. list price of roughly $6,500 per year, inclisiran has already faced real-world adoption hurdles tied to insurance coverage and clinic logistics. A one-time gene-editing infusion would likely carry a much higher upfront cost, but the economic math could look different if a single treatment eliminates decades of drug refills, follow-up visits, and the downstream expense of cardiovascular events in patients who quietly stop taking their pills.
What the data cannot yet answer
Twelve months of follow-up is long enough to show that VERVE-102’s effect does not fade quickly. It is not long enough to prove the edit lasts a lifetime, or to catch rare complications that surface only after years. Cardiovascular disease unfolds over decades, and regulators will almost certainly require multi-year safety and efficacy data before any one-time gene edit can credibly replace chronic statin therapy for broad populations.
No head-to-head trial has compared VERVE-102 against inclisiran. The two therapies target the same protein and aim at overlapping patient groups, but their risk profiles differ in a fundamental way. Inclisiran wears off. If a patient develops an unexpected problem, the next dose can simply be skipped and the drug clears the system. A permanent DNA change offers no such off-switch. Whether that permanence translates into better long-term cardiovascular outcomes, or introduces risks that periodic dosing avoids, is an open question no existing trial has been designed to answer.
There is also the question of who would qualify. Current inclisiran approvals are limited to high-risk patients whose cholesterol remains uncontrolled on statins. Extending a permanent gene edit to people at more moderate risk would require a level of long-term safety confidence that does not yet exist. Verve Therapeutics has not publicly disclosed a timeline for larger Phase 2 or Phase 3 studies, though the company has indicated that further clinical development is planned.
Separate preclinical work hints at a possible middle path. A study published in Nature showed that a technique called hit-and-run epigenome editing achieved durable silencing of the Pcsk9 gene in mouse liver for close to a year without permanently altering the DNA sequence. That approach is distinct from VERVE-102’s base editing, but it suggests future therapies might silence cholesterol genes reversibly, lowering the stakes if something goes wrong. Mouse results do not reliably predict human outcomes, so the finding is best read as a signal of where the field is heading rather than proof that any specific therapy will work the same way in patients.
Why adherence is the variable that changes the math
Clinical trials tend to overstate what daily pills accomplish in the real world because participants are monitored closely and reminded to take their medication. Outside that controlled setting, adherence drops sharply. Research published in JAMA and subsequent meta-analyses has consistently found that roughly half of patients prescribed statins stop taking them within a year, driven by side effects like muscle pain, pill fatigue, or simple forgetfulness. Every missed dose is a small opening for LDL to climb back toward dangerous levels.
Long-acting injections and one-time gene edits are, in part, attempts to engineer around that human behavior by front-loading the effort into a clinic visit. For patients who cannot tolerate statins or who struggle with daily adherence, these approaches could lock in LDL control in a way that no pill bottle can. That practical advantage is separate from the pharmacology, but it may matter just as much for real-world outcomes.
Where this leaves patients and clinicians in 2026
The evidence as of mid-2026 supports a clear but limited conclusion. Silencing PCSK9, whether through RNA interference or base editing, can produce large and lasting LDL reductions. At least one PCSK9-targeting injection has already met the FDA’s standards for safety and efficacy in narrowly defined high-risk groups. And a single gene-editing infusion has now shown, in a small early trial, that it can hold LDL down for a full year.
What the data do not yet show is that a permanent edit outperforms a reversible injection on the outcomes that matter most: heart attacks, strokes, and survival. Nor do they show that the long-term risk profile of a one-time DNA change is fully understood. For patients and their doctors, the safest read is that VERVE-102 is a genuinely promising experimental therapy in a field that is moving fast, but it is not yet a proven replacement for existing care. The next round of larger, longer trials will determine whether a single shot can truly retire the daily statin pill for good.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
